HCW Biologics Inc. announced the successful development of second-generation, multi-specific T-cell engagers against solid tumors, specifically pancreatic cancer, utilizing its novel proprietary TRBC product discovery and development platform technology. These engagers are designed to activate T cells and simultaneously reduce immunosuppression in the tumor microenvironment.
The company's two lead T-cell engagers target tissue factor and mesothelin, which are established solid tumor antigens. Preclinical studies demonstrated potent and antigen-specific anti-pancreatic cancer activities both in vitro and in humanized mouse models at well-tolerated dose levels.
Dr. Hing C. Wong, Founder and CEO, reported that after treatment with these TRBC-based T-cell engagers, there was 100% survival among tumor-bearing mice in the test group, whereas none of the untreated mice survived. These findings position the program for potential high-value corporate partnerships.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.